Paeds Cases · ophthalmology
Colour vision deficiency and inherited retinal disease: Case
Clinical long case of a ten-month-old infant presenting with the roving eye movements, the nystagmus and the poor fixation, covering the electroretinography and the molecular genetic testing, the RPE65 Leber congenital amaurosis, the voretigene neparvovec gene therapy, the genetic counselling, and the contrast with the benign congenital red-green colour vision deficiency of the older brother.
On this page
Study tools
Target exams
Framing the case
This ten-month-old infant has the classic presentation of a severe congenital retinal dystrophy, the roving eye movements, the nystagmus and the poor fixation with the otherwise normal development, and the framework that organises the case is the electroretinography, the molecular genetic testing and the RPE65 Leber congenital amaurosis. The contrast with the older brother, who carries the benign red-green colour vision deficiency, is the contrast the examiner will probe, because the brother has the stable defect of the normal acuity while the infant has the severe vision loss of the congenital dystrophy. The first priority is the prompt referral to the paediatric ophthalmology service for the electroretinography and the genetic testing, because the treatable RPE65 form must not be missed. [1][3]
Confirming the diagnosis
The ophthalmology service performs the full-field electroretinography, which shows the near-absent rod and cone response, and the pattern electroretinography of the macular pathway, which is also severely reduced. The optical coherence tomography assesses the viability of the retinal cells, which the gene therapy demands, and the fundus autofluorescence maps the retained retina. The molecular genetic testing by the next-generation sequencing panel of the inherited retinal disease genes identifies the biallelic RPE65 mutation, which is the result that opens the door to the gene therapy. The candidate who holds the electrophysiology, the imaging and the panel as the three pillars of the diagnosis earns the marks. [1][9]
The contrast with the colour-deficient brother
References7ShowHide
- [1]Hartong DT, Berson EL, Dryja TP Retinitis pigmentosa. Lancet, 2006.PMID 17113430
- [2]Georgiou M, Robson AG, Fujinami K, et al. Phenotyping and genotyping inherited retinal diseases: Molecular genetics, clinical and imaging features, and therapeutics of macular dystrophies, cone and cone-rod dystrophies, rod-cone dystrophies, Leber congenital amaurosis, and cone dysfunction syndromes. Prog Retin Eye Res, 2024.PMID 38278208
- [3]Russell S, Bennett J, Wellman JA, et al Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet, 2017.PMID 28712537
- [4]Maguire AM, Russell S, Wellman JA, et al Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology, 2019.PMID 31443789
- [6]Birch J Worldwide prevalence of red-green color deficiency. J Opt Soc Am A Opt Image Sci Vis, 2012.PMID 22472762
- [9]Sheck LHN, Esposti SD, Mahroo OA, et al. Panel-based genetic testing for inherited retinal disease screening 176 genes. Mol Genet Genomic Med, 2021.PMID 33749171
- [11]Tan TE, Sun CZY, Poh SSJ, et al. One down but many more to go: the state of gene therapy for inherited retinal disease. Regen Med, 2025.PMID 41054259